EVALUATION OF COMMON POLYMORPHISMS OF CYP2C19 IN CLOPIDOGREL-TREATED PATIENTS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

POOPAK B.; TAGHDISI SH.; HEIDARI M.; FALLAHI P.; KHOSRAVIPOUR G.; BOLOURIAN SH.; GOLKAR T.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON) Year:2014 | Volume:11 | Issue:3 Page(s): 190-196

Download Full-Text

Persian Verion

View:

952

Download:

Cites:

Information Journal Paper

Title

EVALUATION OF COMMON POLYMORPHISMS OF CYP2C19 IN CLOPIDOGREL-TREATED PATIENTS

Author(s)

Keywords

CLOPIDOGRELQ2

GENETIC POLYMORPHISMQ2

CYP2C19 ٬Q2

HUMANQ2

ISCHEMIC HEART DISEASEQ2

Abstract

Background and Objectives: CLOPIDOGREL is one of the most commonly prescribed drugs to prevent ischemic events following coronary syndromes or stent placement. The objective of this study was to evaluate the prevalence of the cytochrome P450 (CYP450) 2C19 enzyme (CYP2C19) genotypes in the Iranian population.Materials and Methods: CYP2C19 (*1/*2/*3) variants were analyzed using Polymerase Chain Reaction-Restriction Length Polymorphism (PCR–RFLP) assays in a representative sample of 154 Iranian patients with ISCHEMIC HEART DISEASE in Peyvand Laboratory.Results: In this study, out of 154 Iranian patients the frequency rates of CYP2C19 *2 were 36 (23.4%) in heterozygous and 6 (3.9%) in homozygous forms; 112 (72.7%) patients had the normal genotype.Conclusions: FDA recommendations are more useful to be practiced in our country than other countries. Physicians should identify patients and advise them to consider other antiplatelet medications or alternative dosing strategies in poor metabolizers.

Cites

No record.

References

Cite

APA: Copy

POOPAK, B., TAGHDISI, SH., HEIDARI, M., FALLAHI, P., KHOSRAVIPOUR, G., BOLOURIAN, SH., & GOLKAR, T.. (2014). EVALUATION OF COMMON POLYMORPHISMS OF CYP2C19 IN CLOPIDOGREL-TREATED PATIENTS. THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON), 11(3), 190-196. SID. https://sid.ir/paper/78698/en

Vancouver: Copy

POOPAK B., TAGHDISI SH., HEIDARI M., FALLAHI P., KHOSRAVIPOUR G., BOLOURIAN SH., GOLKAR T.. EVALUATION OF COMMON POLYMORPHISMS OF CYP2C19 IN CLOPIDOGREL-TREATED PATIENTS. THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON)[Internet]. 2014;11(3):190-196. Available from: https://sid.ir/paper/78698/en

IEEE: Copy

B. POOPAK, SH. TAGHDISI, M. HEIDARI, P. FALLAHI, G. KHOSRAVIPOUR, SH. BOLOURIAN, and T. GOLKAR, “EVALUATION OF COMMON POLYMORPHISMS OF CYP2C19 IN CLOPIDOGREL-TREATED PATIENTS,” THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON), vol. 11, no. 3, pp. 190–196, 2014, [Online]. Available: https://sid.ir/paper/78698/en

Related Journal Papers